2017 KOL Breakfast Event (Live)
06/27/17 at 8:30 a.m. ET
OverviewOtonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, and has achieved positive pivotal trial results in patients with acute otitis externa. OTO-104 is a steroid in development for the treatment of Ménière's disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expected to be initiated in the second half of 2017. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.
|Recent News||More >>|
|Upcoming Events||More >>|
|Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|